Ivermectin Politics Collide With COVID Booster Restrictions in U.S.
In 2025, U.S. healthcare is once again navigating a turbulent mix of vaccine policy, drug misinformation, and political rhetoric....
Ivermectin’s Place Amid J&J’s $2B U.S. Drug Manufacturing Expansion
In 2025, Johnson & Johnson (J&J) announced a $2 billion investment to expand its U.S. drug manufacturing capacity, strengthening the country’s ability.....
